Hirtle Callaghan & Co’s Thermo Fisher Scientific TMO Stock Holding History

Hirtle Callaghan & Co’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,042	Closed	-$1M	–	133
2026 Q1	$1M	Sell	2,042 -61	-3%	-$33.1K	0.03%	63
2025 Q4	$1.22M	Buy	2,103 +25	+1%	+$14.1K	0.04%	60
2025 Q3	$1.01M	Sell	2,078 -16	-0.8%	-$7.45K	0.04%	62
2025 Q2	$849K	Buy	2,094 +94	+5%	+$39.3K	0.03%	66
2025 Q1	$995K	Buy	+2,000	New	+$1.08M	0.04%	67
2024 Q1	–	Sell	-685	Closed	-$364K	–	106
2023 Q4	$364K	Buy	+685	New	+$332K	0.02%	78
2023 Q2	–	Sell	-1,106	Closed	-$637K	–	86
2023 Q1	$637K	Sell	1,106 -8,059	-88%	-$4.54M	0.03%	59
2022 Q4	$5.05M	Buy	9,165 +4,520	+97%	+$2.4M	0.31%	33
2022 Q3	$2.36M	Sell	4,645 -2,771	-37%	-$1.55M	0.17%	46
2022 Q2	$4.03M	Sell	7,416 -416	-5%	-$229K	0.24%	33
2022 Q1	$4.63M	Buy	7,832 +5,722	+271%	+$3.29M	0.22%	33
2021 Q4	$1.41M	Buy	+2,110	New	+$1.32M	0.07%	47
2014 Q3	–	Sell	-850	Closed	-$100K	–	624
2014 Q2	$100K	Buy	+850	New	+$100K	0.01%	291

Other funds holding TMO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Hirtle Callaghan & Co's TMO Position: Q2 2026 in Review

Hirtle Callaghan & Co sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 2,042 shares — an estimated $1M sold.

Hirtle Callaghan & Co first reported a position in TMO in Q2 2014 and held it in 13 quarters. The position peaked at $5.05M in Q4 2022. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

Hirtle Callaghan & Co reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
Hirtle Callaghan & Co sold 2,042 Thermo Fisher Scientific shares in Q2 2026, an estimated $1M.
Hirtle Callaghan & Co first reported a position in Thermo Fisher Scientific in Q2 2014 and held it in 13 quarters.
Hirtle Callaghan & Co's Thermo Fisher Scientific position peaked at $5.05M in Q4 2022.
2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Hirtle Callaghan & Co's 13F filing for Q2 2026, filed 14 Aug 2026.